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Purpose: The pterygium is characterized by a fibrovascular neoformation from the bulbar conjunctiva into the cornea.
The recent discovery that abnormal markers associated with tumor diseases are identified in the pterygium strengthens
the theory that the pterygium is a tumor-like disease rather than a degenerative disease. The CD30 molecule has been
identified in neoplastic and normal epithelial proliferating cells. The aim of this study was to determine the expression of
the CD30 molecule in the pterygium.
Methods: Immunohistochemical staining using an antibody to CD30 and to the Ki-67 nuclear antigen was performed on
25 pterygial specimens and 10 healthy conjunctivas.
Results: Strong immunostaining against CD30 was observed in all pterygium specimens, in contrast to the healthy
conjunctivas that showed weak immono-positivity in only three cases. The staining was diffused, predominantly to the
basal epithelium. The Ki-67 antigen was observed in the nucleus of the basal epithelium of the pterygial specimens, and
no staining was observed in the healthy conjunctiva. When serial sections were stained with CD30 and Ki-67, the cells
that expressed CD30 also expressed Ki-67.
Conclusions: The present study identified for the first time the existence of CD30 molecules in the basal epithelium of a
pterygium. The fact that the positivity to Ki-67 in the basal epithelium of the pterygium correlated with the CD30 reactivity
suggested that this protein could be associated with the uncontrolled cell proliferation of the epithelium in this pathology.
The CD30 molecule could therefore be a suitable target to be inhibited using chimerical antibodies in pterygium diseases.
A  pterygium  is  one  of  the  most  frequent  diseases  in
ophthalmology. This lesion is characterized by fibrovascular
neoformation from the bulbar conjunctiva into the cornea and
is composed of epithelium and highly vascular, subepithelial,
loose connective tissue. The pterygium has been considered a
chronic degenerative condition. Although the pathogenesis of
pterygium is not clearly understood, the immunopathological
process behind a pterygium has been investigated [1].
Certain  findings  concerning  common  features  in  a
pterygium  and  neoplasia  have  been  proposed,  raising  the
possibility  that  a  pterygium  is  a  neoplastic-like  growth
disorder [2]. The finding of tumor markers in the biopsies of
pterygium lesions such as the p53 tumor suppressor gene,
increased cell cycle proteins such as Ki-67 and cyclin D1
proteins, and a decrease of cyclin dependent kinase inhibitor
p27 strengthen the hypothesis that a pterygium resembles a
tumor-like  lesion  [3].  Other  evidence  includes  the
overexpression  in  a  pterygium  of  the  cyclooxigenase-2
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protein [4], which is associated with UV-induced cutaneous
tumorigenesis [5,6].
The CD30 molecule is a protein that belongs to the tumor
necrosis factor receptor family. It was identified for the first
time on Reed-Sternberg cells of Hodgkin’s disease [7]. To
date, CD30 has been recognized as a pleiotropic molecule that
may drive either cell proliferation or apoptosis depending on
the microenvironment, and it has clearly been associated with
the  etiology  of  diverse  neoplastic  diseases,  including
intraocular  T-cell  lymphoma  [8].  Although  CD30  protein
expression  is  predominantly  in  lymphoid  cells,  such  as
activated T and B cells, recent findings have determined that
the expression of the CD30 molecule has been identified in
newborn  non-neoplastic  skin  basal  epithelial  cells  [9],
suggesting  that  CD30  is  also  expressed  by  epithelial
proliferating and differentiating cells for which the origin is
not lymphoid. The association of CD30 expression with the
progression of tumors and diseases other than neoplasias has
been described as allergic and infectious diseases [10,11].
On the other hand, Ki-67 is a molecule associated with
cell  proliferation  and  the  expression  of  this  molecule  in
conjunction  with  other  molecules,  such  as  COX-2,  has
recently  been  related  to  the  development  of  preneoplasic
lesions [12].
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2068In  order  to  establish  new  knowledge  regarding  the
immunopathology of a pterygium, the aim of this work was
to determine the expression and tissue localization of the
CD30 molecule in biopsies from a primary pterygium and to
compare it to healthy conjunctiva.
METHODS
Twenty-five primary pterygia and 10 healthy conjunctivas
were collected after informed consent was obtained from each
patient  who  underwent  a  surgical  procedure.  Samples  of
healthy conjunctiva were obtained from the same patients who
underwent a pterygium surgical excision. The biopsies of the
healthy conjunctivas were taken from the autografts obtained
from the superior bulbar conjunctiva and, unfortunately, 15
out of the 25 specimens were not sufficient for this study. The
excision of the pterygium was performed simply, without
using mytomicin C or radiation in the surgical procedure.
Tissue segments were fixed by 10% formalin overnight and
processed for paraffin embedding. Sections of 5 µm were cut
and mounted on glass polylysine-charged slides. All slides
were then deparaffinized and rehydrated with a gradient of
ethanol concentrations. Antigen retrieval was performed by
heating the samples in 10 mmol/l citrate buffer (pH 6.0).
Samples were washed with 0.1%Tween-PBS (pH 7.3); this
buffer was used for all subsequent washes. Primary antibodies
were the ready-to-use mouse anti-human CD30 monoclonal
antibody (Dako, Glostrup, Denmark) and the mouse anti-
human  Ki-67  monoclonal  antibody  (Biocare  Medical,
Concord, CA) diluted at 1:50; both primary antibodies were
incubated at room temperature (RT) for 30 min. Samples were
washed twice. All samples were incubated for 30 min with
universal  biotinylated  secondary  antibodies  at  RT.  The
samples were washed twice and a final incubation of 30 min
at RT was performed using streptavidin-peroxidase. Signals
were developed using 3, 3’-diaminobenzidine for 5 min and
counterstained with Mayer’s hematoxylin (Dako, Glostrup
Denmark). Negative controls were performed by leaving out
the  primary  antibody.  Protein  expression  of  CD30  was
identified in Hodgkin’s lymphoma (Figure 1A) and was used
as  a  positive  control  for  this  molecule.  Similarly,  human
tonsils  were  used  as  positive  controls  for  Ki-67
immunostaining (Figure 1B). At least 100 pterygium basal
epithelial cells in four microscopic fields from the tissue were
counted. Positive staining cells were noted by their labeling
index as a percentage in each specimen, and the measurements
were averaged.
RESULTS
Normal bulbar conjunctiva: Conjuctival epithelium consisted
of several layers of round cells without keratinization; few
goblet cells were found intermingled (Figure 2A,B). Weak
immunoreactivity  to  CD30  was  identified  in  three  (30%)
normal conjunctivas stained mainly in the basal epithelium
and  only  two  (20%)  of  the  three  cases  of  normal  bulbar
conjunctiva were identified in the stromal side of the tissue.
Immunoreactivity  to  Ki-67  was  not  found  in  all  of  the
conjunctivas studied in the epithelial cells or in the stromal
side (data not shown).
Pterygium: Histological findings showed that epithelial cells
consisted of several layers without nuclear atypia and goblet
cell hyperplasia was also observed. In the stroma, numerous
microvessels and fibroblasts with elastic degeneration were
identified (Figure 2C). Unlike normal bulbar conjunctiva, a
strong immunoreactivity to CD30 was identified mainly in the
basal  epithelium  (Figure  2D)  and  in  the  parabasal  and
superficial epithelium; however, the expression was not as
strong and was presented in fewer studied pterygia cases.
When analysis was performed on the stroma of the pterygium,
infiltrating  cells  were  identified.  From  these  cells,  some
presented positive immunoreactivity to CD30. Likewise, the
Figure 1. Immunohistochemistry for CD30 and Ki-67. Reed-Sternberg cells are positive for CD30 identified in Hodgkin’s disease (A). Nuclear
expression of Ki-67 identified in human tonsils (B). Both slides were counterstained with Mayer’s hematoxylin (400×).
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2069perivascular immuno-reactivity of CD30 was also observed.
The staining pattern observed was granular with cytoplasmic
and perinuclear localization (Figure 3 and inset).
The expression of the Ki-67 antigen was also observed in
all pterygia stained with this antibody. Ki-67 staining was
confined to the nucleus of the cells from the basal epithelium.
No other structures presented immunoreactivity to the Ki-67
antibody. When serial sections were performed, the same cells
were stained with both CD30 and Ki-67antibodies identified
mostly in the basal epithelium (Figure 4). Table 1 summarizes
the number of immunopositive cells.
Figure  2.  Hematoxylin  and  eosin
staining for healthy conjunctiva (A) and
pterygium  (C)  and  immunoreactivity
for CD30 in healthy conjunctiva (B) and
pterygium (D). The arrow indicates the
strong  immunoreactivity  in  the  basal
epithelium (400×).
Figure  3.  Immunohistochemistry  with
the  CD30  antibody  of  a  pterygium.
Representative  microphotograph
(100×)  of  a  pterygium  stained  with
CD30. The arrow indicates the strong
immunoreactivity  of  CD30
predominantly  in  basal  epithelium  in
comparison  to  the  weak  reactivity  to
CD30  in  parabasal  and  superficial
epithelium.  The  asterisk  indicates
perivascular  immunostaining  with
strong immunoreactivity to CD30. The
strong perivascular staining of CD30 is
shown  by  arrowheads  in  the  inset  at
higher magnification (400×).
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2070DISCUSSION
In the present study, CD30 was identified preferentially in
pterygium  tissue  compared  with  normal  conjunctiva,  and
CD30  expression  was  demonstrated  preferentially  in
pterygium  basal  epithelium,  stromal  infiltrating  cells,  and
perivascular  areas.  Similarly,  Ki-67  was  localized  in  the
pterygium  epithelial  basal  cells  and  the  positivity  was
confined to the nucleus of the cells. This immunostaining was
not observed in healthy conjunctivas. There are many studies
that tried to identify the etiology of pterygium disease with
vast evidence that a pterygium is a growth disorder resulting
from uncontrolled cell proliferation rather than a degenerative
process [13]. The expression of the CD30 molecule has been
widely studied in neoplastic diseases, such as lymphomas
[14-16], and it has recently been identified in non-lymphoid
tissue as skin associating its expression with proliferation and
differentiation [9]. Although the CD30 expression has been
identified as transmembranal [17], the staining pattern in a
pterygium is mostly cytoplasmic and perinuclear. This result
is in accordance with other authors who found that the cells
with a positive reaction to CD30 in epithelial cells from skin
manifested a fine brown nuclear reaction [9], suggesting a
different localization of this antigen rather than a membrane
expression, which is supported by other authors who have
shown a cytoplasmic and Golgi localization of the CD30
molecule [18,19].
Pterygium tissue consists of cell hyperplasia, including
goblet cell hyperplasia [20]. The goblet cells of a pterygium
and healthy conjunctiva were negative to both CD30 and
Ki-67  immunostaining,  suggesting  that  the  proliferation
action of CD30 is not driven directly by CD30’s function. In
this study, Ki-67 was expressed in basal epithelium; these
results are in accordance with those found by Kase et al., who
demonstrated that the expression of Ki-67 in a pterygium was
confined to epithelial cells rather than fibroblasts and goblet
cells [3]. When the immunohistochemistry of both CD30 and
Ki-67 on pterygium samples was performed, the same cells
were stained with these two antibodies, suggesting a strong
correlation between CD30 and cell proliferation.
Unlike in goblet cells, the strong immunoreactivity of
CD30 molecule was observed in the basal epithelium of a
pterygium, suggesting that these cells were proliferating and
probably the abnormal expression of CD30 in these cells
determined the uncontrolled cell proliferation reported in a
pterygium [13]. As supported by other authors, CD30 has been
identified in epithelial cells in the basal germinative layer of
the epidermis [9] and placenta [21-23], which suggested that
this molecule was expressed by epithelial proliferating and
differentiating cells of other than lymphoid origin.
In this study, CD30 was identified in some of infiltrating
cells. Whether these cells possess proliferating activity is still
being studied. Detection of CD30 on perivascular regions
could be associated with infiltrating lymphocytes that present
Figure  4.  Immunohistochemistry  for
CD30 and Ki-67 in serial sections of
pterygium  tissue.  Representative
microphotograph  of  CD30
immunopositive cells are shown in A, a
serial  section  is  shown  in  B  for  the
nuclear localization of Ki-67. Note that
the arrows indicate the same cells that
are positive to both antigens (400×).
TABLE 1. NUMBER OF CELLS POSITIVE AND NEGATIVE TO BOTH CD30 AND KI-67 ON BASAL EPITHELIUM OF PTERYGIUM.
CD30+ CD30- Ki-67+ Ki-67
65% (±3.5%) 38.3% (± 3.1%) 63.3% (±7.3%) 36.6% (±7.3%)
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2071this antigen [24]; however, the possibility of immunoreaction
directly on the endothelial cells cannot be ruled out [25]. The
evidence that CD30 protein expression in epithelial cells from
a  pterygium  was  associated  with  proliferation  rather  than
apoptosis suggested that this molecule was a potential target
for biological therapy of treating a pterygium with chimerical
anti-CD30 monoclonal antibodies [26] and this could lead to
new perspectives in the therapy of this common disease.
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